Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab

Abstract The early remission of diabetic macular edema (DME) often occurs in eyes treated with anti-vascular endothelial growth factor (VEGF) treatment. We retrospectively reviewed and characterized eyes with early remission of DME at six months in 80 eyes under pro re nata (PRN) intravitreal ranibi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatsuya Yoshitake, Tomoaki Murakami, Kiyoshi Suzuma, Masahiro Fujimoto, Yoko Dodo, Akitaka Tsujikawa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4e45db775cc64c1a91f4546776fa7729
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4e45db775cc64c1a91f4546776fa7729
record_format	dspace
spelling	oai:doaj.org-article:4e45db775cc64c1a91f4546776fa77292021-12-02T15:08:47ZPredictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab10.1038/s41598-019-44078-62045-2322https://doaj.org/article/4e45db775cc64c1a91f4546776fa77292019-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-019-44078-6https://doaj.org/toc/2045-2322Abstract The early remission of diabetic macular edema (DME) often occurs in eyes treated with anti-vascular endothelial growth factor (VEGF) treatment. We retrospectively reviewed and characterized eyes with early remission of DME at six months in 80 eyes under pro re nata (PRN) intravitreal ranibizumab (IVR) injections. The number of eyes without center-involved DME gradually increased and 14 and 20 eyes achieved remission of DME at 3 or 6 months, respectively, under the PRN regimen following three monthly loading doses. In particular, eyes with early remission at 6 months had smaller CSF thickness than those without the remission before and after the treatment except at the 1-month visit (P < 0.05); however, the changes in CSF thickness did not differ between them. VA and its changes were not different between eyes with and without remission. Multivariate analysis revealed that smaller CSF thickness at baseline predicted the early remission of DME under PRN IVR injections (odds ratio, 0.989; 95% confidence interval, 0.982–0.997; P = 0.008). These data elucidate the clinical characteristics of early remission of DME under PRN IVR injections and suggest that smaller CSF thickness at baseline is a novel predictor of early remission under PRN IVR injections for DME.Tatsuya YoshitakeTomoaki MurakamiKiyoshi SuzumaMasahiro FujimotoYoko DodoAkitaka TsujikawaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 9, Iss 1, Pp 1-7 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tatsuya Yoshitake Tomoaki Murakami Kiyoshi Suzuma Masahiro Fujimoto Yoko Dodo Akitaka Tsujikawa Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
description	Abstract The early remission of diabetic macular edema (DME) often occurs in eyes treated with anti-vascular endothelial growth factor (VEGF) treatment. We retrospectively reviewed and characterized eyes with early remission of DME at six months in 80 eyes under pro re nata (PRN) intravitreal ranibizumab (IVR) injections. The number of eyes without center-involved DME gradually increased and 14 and 20 eyes achieved remission of DME at 3 or 6 months, respectively, under the PRN regimen following three monthly loading doses. In particular, eyes with early remission at 6 months had smaller CSF thickness than those without the remission before and after the treatment except at the 1-month visit (P < 0.05); however, the changes in CSF thickness did not differ between them. VA and its changes were not different between eyes with and without remission. Multivariate analysis revealed that smaller CSF thickness at baseline predicted the early remission of DME under PRN IVR injections (odds ratio, 0.989; 95% confidence interval, 0.982–0.997; P = 0.008). These data elucidate the clinical characteristics of early remission of DME under PRN IVR injections and suggest that smaller CSF thickness at baseline is a novel predictor of early remission under PRN IVR injections for DME.
format	article
author	Tatsuya Yoshitake Tomoaki Murakami Kiyoshi Suzuma Masahiro Fujimoto Yoko Dodo Akitaka Tsujikawa
author_facet	Tatsuya Yoshitake Tomoaki Murakami Kiyoshi Suzuma Masahiro Fujimoto Yoko Dodo Akitaka Tsujikawa
author_sort	Tatsuya Yoshitake
title	Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
title_short	Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
title_full	Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
title_fullStr	Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
title_full_unstemmed	Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
title_sort	predictor of early remission of diabetic macular edema under as-needed intravitreal ranibizumab
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/4e45db775cc64c1a91f4546776fa7729
work_keys_str_mv	AT tatsuyayoshitake predictorofearlyremissionofdiabeticmacularedemaunderasneededintravitrealranibizumab AT tomoakimurakami predictorofearlyremissionofdiabeticmacularedemaunderasneededintravitrealranibizumab AT kiyoshisuzuma predictorofearlyremissionofdiabeticmacularedemaunderasneededintravitrealranibizumab AT masahirofujimoto predictorofearlyremissionofdiabeticmacularedemaunderasneededintravitrealranibizumab AT yokododo predictorofearlyremissionofdiabeticmacularedemaunderasneededintravitrealranibizumab AT akitakatsujikawa predictorofearlyremissionofdiabeticmacularedemaunderasneededintravitrealranibizumab
_version_	1718387996514844672

Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab

Ejemplares similares